Abstract
Introduction

Heart disease and atherosclerosis still represent the leading causes of morbidity and mortality worldwide. The lack of suitable autologous grafts has produced a need for artificial grafts but the patency of these grafts is limited in comparison to natural materials. Tissue engineering, of blood vessels, cardiovascular structures and whole organs holds promises as a new approach for creating replacement tissues to repair congenital defects and/or diseased tissues. Current artificial grafts carry significant limitations, including thrombosis, infection, limited durability and inability to grow. In an attempt to surmount these shortcomings, creation of tissue-engineered cardiovascular vascular grafts (TECVG), constructs by using cultured autologous vascular wall cells seeded onto a synthetic biodegradable polymer scaffold, have been developed [1, 2]. Autologous TECVGs have the potential advantages of growth, durability, resistance to infection, and freedom from problems of rejection, thrombogenicity and donor scarcity. Both pre-clinical and clinical studies have demonstrated the feasibility of constructing functional large-diameter (6 mm) vascular grafts from autologous vascular cells seeded onto a biodegradable tubular matrix
. 
Until now several types of polymers have been proposed to obtain vascular grafts and poly(lactic-co-glycolic acid) polymers (PLGA) and poly-L-lactic acid (PLLA) represent the most attractive avenue for this
purpose as their advantageous mechanical properties, plasticity and biocompatibility [6] . These [7] .
Moreover, polymers engrafted with growth factors, cytokines and drugs have been developed [8] [9] [10] , thus obtaining drugreleasing systems capable of focused and localized delivery of molecules depending on the environment requirements and the actual milieu in which the scaffold is placed. A broad range of applications for electrospun fibres have been suggested [11, 12] ranging from drug delivery [13] [14] [15] [16] [17] to gene therapy [18] . [19, 20] . Local sustained delivery of various growth factors such as epidermal growth factor [21] , transforming growth factor (TGF) [22] , vascular endothelial growth factor (VEGF) [23, 24] and bone morphogenic proteins (BMPs) [25] within the biodegradable scaffolds has been used to stimulate the differentiation of seeded cells to desirable specific organized tissues. To this extent, because of their biochemical properties, it is possible to produce growth factor microspheres to encapsulate within polymeric biomaterials or direct incorporate into the void space of the scaffolds to achieve sustained release [20] . [26] . Recently, bone marrow stem cells were seeded into macroporous biodegradable polymer scaffolds and implanted to regenerate or heal injured tissues [27] . Previously [42] [43] [44] leading to implant necrosis [45] . Carrier et al. [46, 47] and Radisic et al. [48] [49] [50] [42, 54] (Fig. 1) [7] . Of late, the electrospinning technique is becoming one of the most effective and functional approaches [56] with the possibility to be combined to the newest methodologies of cell seeding [57, 58] [64] . [42, 55, [66] [67] [68] [69] . Growth factors can be adsorbed to the scaffold [70] [70] .
However, in many cases of tissue-engineering applications, cell differentiation towards a specific phenotype is highly desirable. In situ local delivery of various drugs and protein growth factors within tissue-forming cell/scaffold constructs has been investigated
In tissue engineering of blood vessels and cardiovascular structures, several autologous cell types have been used to seed the constructs in particular endothelial cells obtained from great saphenous vein even if this raise a good number of issues concerning cells amount and availability
These peptide scaffolds can be further functionalized through direct solid-phase synthesis extension of short-sequence motifs from two major proteins of the basement membrane, laminin 1 (YIGSR, RYVVLPR) and collagen IV (TAGSCLRKFSTM). It has been shown that these tailor-made scaffolds increased the formation of
It is also possible to blend growth factor containing microspheres into the scaffold [71] [40] .
Alternatively, a direct mixing growth factor containing protein powder into the scaffold during processing can be performed [24, 53, 72] .
Adsorbing growth factor onto the scaffold has the drawback of low loading efficiencies and rapid release together with the degradation of growth factors such as rhVEGF, bone morphogenetic protein 4 (BMP-4) and bFGF during a very short release time [70] PLGA microspheres/poly(vinyl alcohol) hydrogel composite [40] VEGF Poly(lactide-co-glycolide) (PLG) [109] Fibrin [222] Collagen [223] Gelatine [224] Alginate [114] PDGF-BB Poly(D,L-lactic-co-glycolic acid) (PLGA) [71] b-FGF Alginate [69] poly(D,L-lactic-co-glycolic acid) (PLGA) [132] Poly(ester urethane)urea [73] Fibrin [225] Gelatine [226] TGF-␤ Gelatine [227] Insulin-like growth factor 1 Self-assembling nanofibres [134] HGF Gelatine [228] Heparin Alginate [81] Chitosan [82] Hyaluronic acid [83] Poly(D,L-lactic-co-glycolic acid) (PLGA) [80] Heparin Poly(epsilon-caprolactone)(PCL) [9] Polymer-coated metallic wires [139] Diazeniumdiolates nitric oxide donor Polyurethane [143] Polyethylene glycol (PEG) [146] Plasmid DNA encoding platelet-derived growth factor (PDGF) gene 
Poly(D,L-lactic-co-glycolic acid) (PLGA) [180]
Hench and colleagues in 1971 that glasses in the system
SiO2-CaO-NaO-P2O5 possess bioactivity, these materials have found use in a wide range of biomedical applications including permanent implants, dentistry, bone reconstruction and tissueengineering scaffolds [84] . More recently, it has been discovered that certain compositions of bioactive glass stimulate a significant increase in the secretion of angiogenic growth factors from fibroblasts and can induce infiltration of a significantly increased number of blood vessels into synthetic scaffolds [85, 86] 
Growth factors
Localized delivery of growth factors using implantable DDSs has been successfully used to achieve site-specific pharmacological effects such as neo-angiogenesis using VEGF [99] [100] [101] [102] and bone growth using BMPs [103, 104] [106] . Moreover, considering the short half-lives of these molecules in vivo [107] [20] . [110] . [71] . Moreover, given its protective action on cardiomyocyte [111] , local myocardial delivery of PDGF by self-assembling peptide nanofibres at the time of myocardial infarction has been attempted, leading to a sustained improvement in cardiac function without induction of cardiac fibrosis or pulmonary hypertension [112] .
. As far as pro-angiogenic growth factor treatment is concerned, considering the limited success in clinical investigations of direct bolus injections of pro-angiogenic growth factors [52, 105], a good piece of literature has been focused on the controlled (i.e. sustained and localized) VEGF delivery from polymeric vehicles. This method has been proving to drive vascularization at a desired tissue site, as indicated by increased microvessel density
PDGF has been demonstrated to promote wound healing through enhancing the formation of granulation tissues, and recombinant human PDGF-BB has been approved by US Food and Drug Administration for use in diabetic foot ulcers
Despite its potential role in tissue regeneration enhancement, clinical application of PDGF encounters some hurdles basically represented by requirement for frequent administrations to maintain sufficient therapeutic concentration. In order to surmount these shortcomings, engineering of biomaterials developed a microsphere-based scaffold release system in which PDGF-BB encapsulated PLGA microspheres were incorporated into a biodegradable PLLA scaffold with well interconnected macroporous and nano-fibrous structures
Polymeric delivery systems allowing localized and sustained release of therapeutic agents may bypass the current limitations of growth factors delivery [113] . Alginate hydrogels may represent an attractive alternative for localized VEGF delivery [114, 115] and recently an injectable biodegradable alginate hydrogel allowing sustained and localized release of VEGF at a desirable concentration has been developed [116] . [117, 118] . [119] .
This system provided a spatiotemporal factor bioavailability leading to a significant angiogenic response in ischemic hind limbs. The importance of a regulated VEGF-induced angiogenesis is demonstrated by the lack of efficient perfusion when an uncontrolled induction of angiogenesis leads to leaky vessels with tortuous profiles that are readily remodelled and eliminated through regression
It is important to focus on the fact that the biocompatibility of the materials currently used does not necessary imply in its sig
The immune system may also affect the functionality of engineered vessels, as invading immune cells secrete angiogenic growth factors and also release these factors from the ECM [120, 121] . Chen and colleagues demonstrated differences in the angiogenic local response in severe combined immunodeficiency (SCID) and immunocompetent mice (C56BL/6) to a porous PLG construct engineered to provide a sustained delivery of VEGF [122] . The VEGF delivered from this system maintained at least 90% bioactivity and induced sprouting angiogenesis from surrounding host vasculature, which infiltrates the highly porous scaffold, resulting in the rapid formation of neovasculature in vivo [20, 123] [125] . Treatment of expanded polytetrafluoroethylene (ePTFE) graft with bFGF in order to increase endothelialization [126, 127] and coating with the peptide sequence Arg-Gly-Asp to improve endothelial cell adhesion through the integrins system, have been performed [128] . [129] . The use of a naturally occurring ECM materials in the form of a decellularized artery as a substrate for an endothelial cell seeded vascular graft, has been experimented with the aim to maintain similar mechanical properties and structure to a native artery [130] [131] .
both within and around the PLG system. The defined area of the scaffold allowed to differentiate between new tissue within the scaffold (i.e. local effects), and the surrounding host tissue (i.e. regional effects), and thus to distinguish between perfusion changes resulting from growth factor-induced angiogenesis (within the scaffold), and the combined effects of angiogenesis and arteriogenesis in the tissue surrounding the scaffold. This study proved that local angiogenesis may be augmented by the combined effects of angiogenesis initiated by the immune response and delivered growth factors, clearly stressing the idea of the need for a careful evaluation of the 'host factor' in tissue engineering of cardiovascular structures. Moreover, dosage of the delivered growth factors has to be considered in order to avoid some potential adverse effects as tumourigenesis. Along with VEGF, b-FGF has been one of the most studied cytokine as for its angiogenic properties. This heparin-binding growth factor is known to induce the proliferation of endothelial cells and has been studied as a potent mitogen for tissue regeneration, wound healing and angiogenesis [124]. In addition, heparinbound bFGF improved recognition by cellular receptors and enhanced mitogenic activity. b-FGF has been widely used for vascular applications. Intracoronary delivery with increased collateralization has been shown
However, those attempts encounter hurdles related to the synthetic graft materials which still present issues including high mechanical stiffness, thrombogenecity and the elicitation of foreign-body reactions. Additionally, endothelialization has been shown not to inhibit intimal thickening in vascular prostheses
Furthermore, b-FGF has been used in an alginate hydrogel sustained delivery system showing, after a subcutaneous implantation, an increase in the number of blood vessels in the granulation tissue even higher than in a VEGF-based similar model [69] . This system could enable maintenance of a growth factor concentration ranging in the therapeutic dosage for a prolonged time window within a distance from the vehicle that is regulated by the effective amount of factor incorporated in the scaffold [69] .
More recently, Guan and colleagues developed a thermoplastic elastomer system to provide a controlled release of bFGF. Biodegradable, PEUU scaffolds in tubular and cylinder forms with the ability to release bioactive bFGF over a 3-week period in vitro have been seeded with murine smooth muscle cells. These scaffolds showed mechanical properties attractive for future application in soft tissue engineering as demonstrated by tensile strength, elongation at break and suture retention studies [73] . The release profile of bFGF from heparin containing PEUU scaffolds was found to be similar to that from PLGA scaffolds and methylidene malonate polymer. Previously, a bFGF-loaded PLGA scaffold fabricated using supercritical CO2 exhibited 45% initial burst release in 1 day [72, 132] . The release of bFGF from methylidene malonate polymer films had over 30% initial burst release in the first day [133] .
These studies clearly demonstrate the possibility to develop a cell-seeded construct that can stimulate local angiogenesis useful for blood vessel and cardiovascular structures tissue engineering.
Additionally, the drug-delivery technology can address issues hampering the effectiveness of stem cell therapy regarding cell engraftment, survival and differentiation engineering the local cellular microenvironment. Davies and colleagues designed self-assembling peptide nanofibres for prolonged delivery of insulin-like growth factor 1, a cardiomyocyte growth and differentiation factor, to the myocardium, using a 'biotin sandwich' approach [134] . The ability to control the intramyocardial environment by delivering growth factors to injured myocardium maybe crucial to preventing heart failure as it might sustain organ function and improve the endogenous regenerative response providing a chemoattractant signal to promote stem cell migration. [135] [136] [137] [138] . Based on the specific affinity between heparin and angiogenic growth factors, and its capability to increase stability against thermal denaturation and enzymatic digestion at physiological conditions, there have been numerous reports about controlled release of growth factors using heparin-conjugated natural polysaccharides such as alginate, chitosan and hyaluronic acid [81] [82] [83] . Recently, heparin has been used in association with biodegradable scaffolds by means of immobilization onto the surface of PLGA constructs to obtain local and sustained delivery of bFGF [80] . [142, 143] . The anionic portions of these compounds spontaneously decompose in solution to release nitric oxide, leaving the amine group as a byproduct [144] with rates of dissociation depending on several factors, such as structure, temperature and pH of solution [145] .
Heparin
Heparin is widely used for a variety of important cardiovascular conditions including deep venous thrombosis, myocardial infarction and to circumvent thrombotic phenomena arising from bare metal stent implantation in coronary arteries
Using this bioactive material authors described a two phases releasing kinetic with a rapid burst during the first 48 [146] . PEG has been shown to resist to protein adsorption, platelet adhesion and bacterial adhesion, and numerous methods have been developed to integrate PEG into biomaterials, including polyurethanes, through co-polymerization and surface modification [147] [148] [149] [150] [151] [152] . The laminin-derived cell adhesive peptide sequence tyrosine-isoleucine-glycine-serine-arginine (YIGSR) increases endothelial cell adhesion and migration [153] 
Gene delivery
Until now several attempts have been done to promote regeneration of blood vessels using tissue-engineering approaches with genes. The idea at the basis of this strategy regards the possibility of inducing cell proliferation and differentiation or the secretion of ECM components for tissue regeneration by the transfection of genes encoding growth factors [155] . For these purposes, it is crucial that the development of controlled DDSs which allow a therapeutic gene to be delivered specifically to the target cell in an appropriate sequence and timing [156] [157] [158] [159] [160] [161] and cationic polymers like polylysine [162] [163] [164] [165] and polyethylenimine, molecularly designed to improve delivery of plasmid DNA to the target site at high expression levels [166] [167] [168] [169] [170] [171] [172] [173] [174] [155, .
This 
